Evidence mapPaperPMID 39201799Full record

ReviewInternational journal of molecular sciences2024

Molecular Aspects in the Development of Type 2 Diabetes and Possible Preventive and Complementary Therapies.

Laura Simon-Szabó, Beáta Lizák, Gábor Sturm, Anikó Somogyi, István Takács, Zsuzsanna Németh

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura Simon-SzabóDepartment of Molecular Biology, Semmelweis University, Tuzolto u. 37-47, 1094 Budapest, Hungary.ORCID 0009-0000-9543-2663
Beáta LizákDepartment of Molecular Biology, Semmelweis University, Tuzolto u. 37-47, 1094 Budapest, Hungary.
Gábor SturmDirectorate of Information Technology Basic Infrastructure and Advanced Applications, Semmelweis University, Üllői út 78/b, 1082 Budapest, Hungary.
Anikó SomogyiDepartment of Internal Medicine and Hematology, Semmelweis University, Baross u., 1085 Budapest, Hungary.
István TakácsDepartment of Internal Medicine and Oncology, Semmelweis University, Koranyi S. u 2/a, 1083 Budapest, Hungary.
Zsuzsanna NémethDepartment of Internal Medicine and Oncology, Semmelweis University, Koranyi S. u 2/a, 1083 Budapest, Hungary.ORCID 0000-0003-2586-6639

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of diabetes, including type 2 diabetes (T2DM), is increasing sharply worldwide. To reverse this, more effective approaches in prevention and treatment are needed. In our review, we sought to summarize normal insulin action and the pathways that primarily influence the development of T2DM. Normal insulin action involves mitogenic and metabolic pathways, as both are important in normal metabolic processes, regeneration, etc. However, through excess energy, both can be hyperactive or attenuated/inactive leading to disturbances in the cellular and systemic regulation with the consequence of cellular stress and systemic inflammation. In this review, we detailed the beneficial molecular changes caused by some important components of nutrition and by exercise, which act in the same molecular targets as the developed drugs, and can revert the damaged pathways. Moreover, these induce entire networks of regulatory mechanisms and proteins to restore unbalanced homeostasis, proving their effectiveness as preventive and complementary therapies. These are the main steps for success in prevention and treatment of developed diseases to rid the body of excess energy, both from stored fats and from overnutrition, while facilitating fat burning with adequate, regular exercise in healthy people, and together with necessary drug treatment as required in patients with insulin resistance and T2DM.

Indexed as

Complementary TherapiesDiabetes Mellitus, Type 2Insulin ResistanceAnimalsExerciseHumansInsulinInsulincomplementary therapyconventional therapyglucose intoleranceinsulin resistanceinsulin signalinglife stylepreventionT2DM

Identifiers

PMID39201799
PMCPMC11354764

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.